We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cannabis stocks and ETFs have surged over the past few months since the Department of Health and Human Services asked the DEA to review its classification of cannabis. Earlier this month, a group of 12 state attorneys general sent a letter to the DEA supporting the reclassification.
Even though 24 states and Washington, D.C., have all legalized weed for recreational use, it remains illegal on the federal level. It is currently classified as a Schedule I drug, alongside heroin and LSD.
The new designation would place it in the same category as anabolic steroids, testosterone, and ketamine.
Cannabis companies currently face adverse taxation, lack access to the financial system, and their shares mostly trade over-the-counter or on Canadian exchanges.
Industry participants and investors were earlier hopeful for a more rapid path to full federal legalization under the Biden administration, but not much progress has been made so far.
The SAFER Banking Act, which would allow cannabis companies to use major financial and banking institutions, passed in the Senate Banking Committee in September, but its fate remains uncertain.
US cannabis companies, particularly multistate operators like Green Thumb Industries (GTBIF - Free Report) , Curaleaf Holdings (CURLF - Free Report) and Verano Holdings (VRNOF - Free Report) , could be the biggest beneficiaries of any reform.
To learn about the AdvisorShares Pure US Cannabis ETF (MSOS - Free Report) , the ETFMG U.S. Alternative Harvest ETF (MJUS) and the Roundhill Cannabis ETF (WEED - Free Report) , please watch the short video above.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Cannabis ETFs: What's Behind the Latest Surge
Cannabis stocks and ETFs have surged over the past few months since the Department of Health and Human Services asked the DEA to review its classification of cannabis. Earlier this month, a group of 12 state attorneys general sent a letter to the DEA supporting the reclassification.
Even though 24 states and Washington, D.C., have all legalized weed for recreational use, it remains illegal on the federal level. It is currently classified as a Schedule I drug, alongside heroin and LSD.
The new designation would place it in the same category as anabolic steroids, testosterone, and ketamine.
Cannabis companies currently face adverse taxation, lack access to the financial system, and their shares mostly trade over-the-counter or on Canadian exchanges.
Industry participants and investors were earlier hopeful for a more rapid path to full federal legalization under the Biden administration, but not much progress has been made so far.
The SAFER Banking Act, which would allow cannabis companies to use major financial and banking institutions, passed in the Senate Banking Committee in September, but its fate remains uncertain.
US cannabis companies, particularly multistate operators like Green Thumb Industries (GTBIF - Free Report) , Curaleaf Holdings (CURLF - Free Report) and Verano Holdings (VRNOF - Free Report) , could be the biggest beneficiaries of any reform.
To learn about the AdvisorShares Pure US Cannabis ETF (MSOS - Free Report) , the ETFMG U.S. Alternative Harvest ETF (MJUS) and the Roundhill Cannabis ETF (WEED - Free Report) , please watch the short video above.